Pulmonx Corporation (LUNG)

6,04 -0,01 (-0,17%) In data: 11:08AM EDT. Mercato aperto.

Pulmonx Corporation

700 Chesapeake Drive
Redwood City, CA 94063
United States
650 364 0400
https://pulmonx.com

Settore/i: Healthcare
Settore: Medical Devices
Impiegati a tempo pieno: 279

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Mr. David A. Lehman	General Counsel & Secretary	651,39k	N/D	1961
Mr. Geoffrey Beran Rose	Chief Commercial Officer	632,29k	N/D	1974
Mr. Steven S. Williamson	CEO, President & Director	N/D	N/D	1973
Mr. Mehul Joshi	Chief Financial Officer	N/D	N/D	1961
Mr. Sri Radhakrishnan	Chief Technical Officer	N/D	N/D	N/D
Ms. Marcee M. Maroney	Vice President of Marketing	N/D	N/D	1970
Sarah Huber	Vice President of Sales (U.S.)	N/D	N/D	N/D
Ms. Lisa Paul	Chief People Officer	N/D	N/D	1964
Mr. Jérôme Erath	Senior VP & GM of Europe Middle-East & Africa	N/D	N/D	N/D
Mr. John B. McKune	VP & Corporate Controller	N/D	N/D	1976

Gli importi risalgono al giorno 31 dicembre 2023 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation. It also offers StratX Lung Analysis Platform, a cloud-based quantitative computed tomography analysis service that offers information on emphysema destruction, fissure completeness, and lobar volume to help identify target lobes for the treatment with Zephyr Valves. The company serves emphysema patients in the United States, Europe, the Middle East, Africa, the Asia-Pacific, and internationally. The company was formerly known as Pulmonx and changed its name to Pulmonx Corporation in December 2013. Pulmonx Corporation was incorporated in 1995 and is headquartered in Redwood City, California.

Governance aziendale

L'ISS Governance QualityScore di Pulmonx Corporation al 1 giugno 2024 è 10. I criteri di valutazione fondamentali sono revisione: 8; Consiglio di Amministrazione: 8; diritti degli azionisti: 8; retribuzione: 10.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.